60 Degrees Pharmaceuticals (SXTP) Capital Expenditures (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Capital Expenditures of $30000.0 for Q1 2026, up 1020.24% year-over-year from $2678.0 in Q1 2025, and down 62.44% quarter-over-quarter from $79881.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Capital Expenditures (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Capital Expenditures for 5 consecutive years, with $30000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 1020.24% year-over-year to $30000.0; the TTM figure through Mar 2026 stood at $167203.0 (up 58.15% YoY), while the FY2025 annual figure was $139881.0, up 34.8% from the prior year.
- Capital Expenditures eased to $30000.0 in Q1 2026 per SXTP's latest filing, from $79881.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $89274.0 in Q2 2024 and bottomed at -$13596.0 in Q3 2023.
- Historically, Capital Expenditures has averaged $25816.6 across 5 years, with a median of $12950.0 in 2023.
- Annual changes were most pronounced in 2023 — Capital Expenditures sank 858.14% — and 2026, when it surged 1020.24%.
- 60 Degrees Pharmaceuticals' Capital Expenditures stood at $31575.0 in 2022, then jumped by 76.72% to $55800.0 in 2023, then tumbled by 75.32% to $13773.0 in 2024, then surged by 479.98% to $79881.0 in 2025, then slumped by 62.44% to $30000.0 in 2026.
- Business Quant data shows SXTP's Capital Expenditures at $30000.0 in Q1 2026, $79881.0 in Q4 2025, and $9999.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 251.02 Mn |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30,000.00 |
| Mar 31, 2026 | 30,000.00 |
| Dec 31, 2025 | 79,881.00 |
| Dec 31, 2025 | 79,881.00 |
| Sep 30, 2025 | 9,999.00 |
| Sep 30, 2025 | 9,999.00 |
| Jun 30, 2025 | 47,323.00 |
| Jun 30, 2025 | 47,323.00 |
| Mar 31, 2025 | 2,678.00 |
| Mar 31, 2025 | 2,678.00 |
| Sep 30, 2024 | 13,773.00 |
| Sep 30, 2024 | 13,773.00 |
| Jun 30, 2024 | 89,274.00 |
| Jun 30, 2024 | 89,274.00 |
| Mar 31, 2024 | 726.00 |
| Mar 31, 2024 | 726.00 |
| Dec 31, 2023 | 55,800.00 |
| Dec 31, 2023 | 55,800.00 |
| Sep 30, 2023 | -13,596.00 |
| Sep 30, 2023 | -13,596.00 |